Abstract 416P
Background
Head and neck cancer is one of the most common malignancies in India, with the highest incidence worldwide. Our aim was to study head and neck sarcomas- tumor types, their treatment strategies, recurrence patterns and survival in patients treated in a tertiary centre in the densely populated Northern India.
Methods
This is a retrospective study of a prospectively maintained database. Patients treated between January 2011- June 2016 at the centre were included. Surgical treatment was wide excision (aim was to get disease free margins within the restrictions of the region). Chemotherapy was mainly doxorubicin-based with drugs like cisplatin, ifosfamide, etoposide, vincristine and cyclophosfamide added as per the histology. Radiotherapy was given as part of the curative treatment in Ewing’s sarcoma. Adjuvant radiation therapy was given in close/involved margins or locally advanced disease in other histologies. Patients with distant or locally advanced disease underwent multimodal management.
Results
The study included 29 cases. Histologies were varied, with the most common type being osteosarcoma, followed by chondrosarcoma. Ewing’s sarcoma, pleomorphic sarcoma and spindle cell sarcoma were the other common types. Most common site of involvement was mandible. Surgery was done in 68.9% (n = 20). High grade disease was seen in 22 patients (75.9%). Margins were clear in 17 patients (80.9%); close margins were documented in 4 patients (19%). Locoregional and distant recurrences occurred in 15% (n = 3) & 10% (n = 2), respectively. Factors affecting the risk of recurrence are high grade, close margins and locally advanced disease. However there is no influence of size, grade or margin status on survival. Median survival was 33 months. The 3 year disease free survival was 52% (95% CI- 0.44-0.83).
Conclusions
Head and neck sarcoma is a rare heterogeneous group in one of the commonest sites of malignancy in India. Apart from appropriate identification of the cases, the better chance of survival is provided by an expert unit with multidisciplinary management, and chance of surgical salvage in case of recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract